New drug combo aims to stop HPV head and neck cancer recurrence
NCT ID NCT07179315
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 34 times
Summary
This study tests whether adding fianlimab to cemiplimab works better than cemiplimab alone at preventing cancer from returning in people with HPV-positive head and neck cancer who have tiny amounts of cancer still detectable after initial treatment. About 68 adults will receive either the combination or cemiplimab alone, and be monitored for recurrence and side effects. The goal is to improve recurrence-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.